← Back to Search

JAK2 Inhibitor

LY2784544 for Blood Cancer

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug for people with myeloproliferative neoplasms, which are diseases that cause too many blood cells to be produced.

Who is the study for?
Adults with blood cancers like polycythemia vera, essential thrombocythemia, or myelofibrosis who haven't responded to or can't tolerate standard treatments (including ruxolitinib) may join. They should have a specific JAK2 mutation (except certain cohorts), be able to swallow pills, not be pregnant or breastfeeding, and agree to use contraception.
What is being tested?
The trial is testing LY2784544 at 120 mg for those with myeloproliferative neoplasms who've had inadequate results from other therapies. It aims to see how well participants respond in terms of disease symptoms and progression.
What are the potential side effects?
While the side effects of LY2784544 are not detailed here, similar medications often cause issues like nausea, diarrhea, liver problems, low blood counts leading to increased infection risk or bleeding tendencies. Side effects vary by individual.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 120 mg LY2784544Experimental Treatment1 Intervention
120 milligram (mg) administered orally once daily for 6 cycles (168 days)

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,679 Previous Clinical Trials
3,465,643 Total Patients Enrolled
Study DirectorEli Lilly and Company

Media Library

LY2784544 (JAK2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01594723 — Phase 2
Blood Cancers Research Study Groups: 120 mg LY2784544
Blood Cancers Clinical Trial 2023: LY2784544 Highlights & Side Effects. Trial Name: NCT01594723 — Phase 2
LY2784544 (JAK2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01594723 — Phase 2
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top